KR102581121B1 - 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제 - Google Patents

2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제 Download PDF

Info

Publication number
KR102581121B1
KR102581121B1 KR1020177004939A KR20177004939A KR102581121B1 KR 102581121 B1 KR102581121 B1 KR 102581121B1 KR 1020177004939 A KR1020177004939 A KR 1020177004939A KR 20177004939 A KR20177004939 A KR 20177004939A KR 102581121 B1 KR102581121 B1 KR 102581121B1
Authority
KR
South Korea
Prior art keywords
delete delete
fluoro
methyl
quinolin
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177004939A
Other languages
English (en)
Korean (ko)
Other versions
KR20170039211A (ko
Inventor
엘리자베트 곤칼베스
크리스틴 토치만
샤우-퐁 옌
수드하 비파군타
지신 종
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102581121(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020237031767A priority Critical patent/KR20230136693A/ko
Publication of KR20170039211A publication Critical patent/KR20170039211A/ko
Application granted granted Critical
Publication of KR102581121B1 publication Critical patent/KR102581121B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020177004939A 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제 Active KR102581121B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237031767A KR20230136693A (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25
US62/028,865 2014-07-25
PCT/IB2015/055561 WO2016012963A1 (en) 2014-07-25 2015-07-22 Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031767A Division KR20230136693A (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Publications (2)

Publication Number Publication Date
KR20170039211A KR20170039211A (ko) 2017-04-10
KR102581121B1 true KR102581121B1 (ko) 2023-09-21

Family

ID=53762251

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177004939A Active KR102581121B1 (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제
KR1020237031767A Ceased KR20230136693A (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237031767A Ceased KR20230136693A (ko) 2014-07-25 2015-07-22 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제

Country Status (31)

Country Link
US (5) US10085993B2 (https=)
EP (2) EP3172209B1 (https=)
JP (3) JP6770946B2 (https=)
KR (2) KR102581121B1 (https=)
CN (2) CN106714784A (https=)
AR (1) AR101286A1 (https=)
AU (4) AU2015293539A1 (https=)
CA (1) CA2954840A1 (https=)
CL (1) CL2017000180A1 (https=)
CO (1) CO2017000586A2 (https=)
DK (1) DK3172209T3 (https=)
EA (2) EA202191301A1 (https=)
EC (1) ECSP17011672A (https=)
ES (1) ES2857523T3 (https=)
FR (1) FR22C1058I2 (https=)
GT (1) GT201700007A (https=)
HU (2) HUE053346T2 (https=)
IL (1) IL250166B (https=)
JO (1) JO3618B1 (https=)
MX (2) MX379279B (https=)
MY (1) MY187276A (https=)
NL (1) NL301208I2 (https=)
NO (1) NO2022058I1 (https=)
PE (1) PE20170523A1 (https=)
PH (1) PH12017500121A1 (https=)
PL (1) PL3172209T3 (https=)
PT (1) PT3172209T (https=)
SG (2) SG11201700147SA (https=)
SI (1) SI3172209T1 (https=)
TW (2) TW202200148A (https=)
WO (1) WO2016012963A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
TWI777658B (zh) 2016-08-10 2022-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
TWI853027B (zh) 2019-05-16 2024-08-21 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
CN114502144A (zh) * 2019-10-24 2022-05-13 韩美药品株式会社 包含抑制癌细胞生长的酰胺衍生物的药物制剂以及包含其的药物产品
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762B (zh) * 2021-02-03 2026-03-06 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
PE20251110A1 (es) * 2022-08-19 2025-04-22 Mirati Therapeutics Inc Composiciones farmaceuticas solidas de adagrasib
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527260A (ja) 2003-06-12 2006-11-30 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 湿式顆粒化で調製されたアトルバスタチンの安定な組成物
WO2011055303A1 (en) * 2009-11-09 2011-05-12 Wyeth Llc Tablet formulations of neratinib maleate
JP2013530243A (ja) 2010-07-06 2013-07-25 ヤンセン ファーマシューティカ エヌ．ベー． 糖尿病のコ−セラピー治療のための製剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
KR20080039876A (ko) 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
WO2009143211A2 (en) * 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
IN2012DN06587A (https=) 2010-02-25 2015-10-23 Bristol Myers Squibb Co
RS54824B1 (sr) * 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
HK1211476A1 (en) 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527260A (ja) 2003-06-12 2006-11-30 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 湿式顆粒化で調製されたアトルバスタチンの安定な組成物
WO2011055303A1 (en) * 2009-11-09 2011-05-12 Wyeth Llc Tablet formulations of neratinib maleate
JP2013530243A (ja) 2010-07-06 2013-07-25 ヤンセン ファーマシューティカ エヌ．ベー． 糖尿病のコ−セラピー治療のための製剤

Also Published As

Publication number Publication date
PT3172209T (pt) 2021-02-11
NZ728089A (en) 2024-01-26
MX2021000595A (es) 2021-04-13
US10596178B2 (en) 2020-03-24
JO3618B1 (ar) 2020-08-27
TW202200148A (zh) 2022-01-01
EA039220B1 (ru) 2021-12-20
EA202191301A1 (ru) 2021-11-30
PE20170523A1 (es) 2017-05-17
HUE053346T2 (hu) 2021-06-28
ECSP17011672A (es) 2018-03-31
HUS2200054I1 (hu) 2023-01-28
MX2017001177A (es) 2017-05-01
AU2015293539A1 (en) 2017-02-02
AR101286A1 (es) 2016-12-07
CO2017000586A2 (es) 2017-06-20
US20250339440A1 (en) 2025-11-06
KR20230136693A (ko) 2023-09-26
WO2016012963A1 (en) 2016-01-28
NL301208I2 (nl) 2025-03-20
AU2020200912B2 (en) 2021-01-28
AU2021202500A1 (en) 2021-05-20
DK3172209T3 (da) 2021-02-22
SG10201900648SA (en) 2019-02-27
EP3172209B1 (en) 2020-12-02
JP2017521469A (ja) 2017-08-03
CL2017000180A1 (es) 2017-09-15
AU2020200912A1 (en) 2020-02-27
SI3172209T1 (sl) 2021-03-31
CN106714784A (zh) 2017-05-24
IL250166A0 (en) 2017-03-30
US20210113569A1 (en) 2021-04-22
FR22C1058I2 (fr) 2023-11-17
AU2018207947A1 (en) 2018-08-09
PH12017500121A1 (en) 2017-05-29
EP3848376A1 (en) 2021-07-14
EA201790259A1 (ru) 2017-06-30
CA2954840A1 (en) 2016-01-28
GT201700007A (es) 2018-12-18
JP2020114852A (ja) 2020-07-30
NO2022058I1 (no) 2022-12-16
TW201613595A (en) 2016-04-16
JP2022046659A (ja) 2022-03-23
MY187276A (en) 2021-09-17
US20220249498A1 (en) 2022-08-11
US10085993B2 (en) 2018-10-02
JP6770946B2 (ja) 2020-10-21
ES2857523T3 (es) 2021-09-29
US12208101B2 (en) 2025-01-28
EP3172209A1 (en) 2017-05-31
IL250166B (en) 2021-01-31
FR22C1058I1 (fr) 2023-01-06
US20170231997A1 (en) 2017-08-17
JP7002587B2 (ja) 2022-01-20
MX379279B (es) 2025-03-11
TWI724993B (zh) 2021-04-21
US20190015418A1 (en) 2019-01-17
BR112017000953A2 (pt) 2017-11-14
SG11201700147SA (en) 2017-02-27
CN115364061A (zh) 2022-11-22
PL3172209T3 (pl) 2021-06-14
KR20170039211A (ko) 2017-04-10

Similar Documents

Publication Publication Date Title
KR102581121B1 (ko) 2-플루오로-n-메틸-4-[7-(퀴놀린-6-일메틸)이미다조[1,2-b][1,2,4]트리아진-2-일]벤즈아미드의 정제 제제
US8883777B2 (en) Compositions controlling pH range of release and/or release rate
TWI744224B (zh) 固形製劑
JP2007500176A (ja) 医薬組成物
HK40049437A (en) Tablet formulation of a c-met inhibitor
HK1231863A1 (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
HK1231863B (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
EA050835B1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
BR112017000953B1 (pt) Comprimido compreendendo 2-flúor-n-metil-4-[7-(quinolin6-il-metil) imidazo[1,2-b][1,2,4]triazin-2-il]benzamida
JP6739275B2 (ja) ゲフィチニブを有効成分とする医薬組成物
JP2020075924A (ja) エルロチニブを有効成分とする医薬錠剤
JP2020090456A (ja) エルロチニブを有効成分とする医薬錠剤
WO2022029798A1 (en) Pharmaceutical compositions comprising ribociclib

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200721

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220328

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230111

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220328

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230111

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220927

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200721

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20230616

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230612

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230111

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220927

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200721

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230918

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230918

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230919

End annual number: 3

Start annual number: 1

PG1601 Publication of registration